Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in Papulopustular Rosacea
NCT07681271Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in papulopustular rosacea comparing Remibrutinib (LOU064) with Placebo (2 arms). Primary endpoint: Absolute change from baseline in facial inflammatory lesion count at 16 weeks. Started Jul 2026; status: recruiting.
02
Drugs
remibrutinib
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT07681271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07681271.